Navigation Links
Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
Date:5/7/2008

Phase II Data Demonstrate Abbott's Most Advanced NNR Candidate ABT-089

Shows Strong Safety, Tolerability And Efficacy in Adults With ADHD

ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and other leading scientists will present new Phase II data showing that ABT-089, a selective neuronal nicotinic receptor (NNR) agonist, is a potentially effective and safe treatment for adults with Attention-Deficit Hyperactivity Disorder (ADHD). The studies are being presented today at the American Psychiatric Association (http://www.psych.org/) 161st Annual Meeting in Washington, D.C.

Phase II study results show that ABT-089 appears to significantly improve the core symptoms of ADHD, improve quality-of-life and work effectiveness, and reduce overall work impairment in adults with ADHD. Data also revealed that ABT-089 appears to be generally well tolerated with no significant negative effects on sleep, appetite or vital signs (heart rate and blood pressure).

ADHD, an ailment historically associated with childhood, persists into adulthood in more than two-thirds of cases. While medical treatment can improve the symptoms of ADHD, currently approved treatments often cause undesirable side effects, including increases in heart rate and blood pressure.

ABT-089 appears to exhibit an improved profile compared to current treatments by improving the core and associated symptoms of ADHD without clinically significant side effects. The compound targets specific types of NNRs found on nerve cells in the central nervous system. NNRs, also known as neuronal nicotinic acetylcholine receptors (nAChRs), modulate the release of several important neurotransmitters, such
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... 2015 , ... Leading CEOs, CSOs, CMOs, and heads of ... prominent academics and key investors for Neuro Advance Boston, October 14, 2015 at ... , Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
...   Synthetic Biologics, Inc. (NYSE Amex: SYN ), ... medicines for serious illnesses, announced today that to improve ... split the roles of Chairman and Chief Executive Officer, ... independent, non-executive Chairman of the Board. Mr. Kraws has ...
... 10, 2012   GeneLink, Inc. (OTC Bulletin ... biotech company, reports financial results for the fiscal year ended ... , The Company reached an agreement in October 2011 ... to Capsalus Corp (OTCBB:WELL.OB, or "Capsalus"). Capsalus assumed management of ...
... Laboratory has entered into a contractual agreement for ancillary ... Network and their 8.6 million lives network. ... pioneer of claims optimization, Stratose (formerly operating as Coalition ... KeyClaims) works to reduce the cost and ensure the ...
Cached Biology Technology:Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 2Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 3GeneLink Reports 2011 Financial Results 2GeneLink Reports 2011 Financial Results 3Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Saudi Arabia Biomedical Sensors Market - Growth, ... The Saudi Arabia Biomedical Sensors market ... CAGR of 3.64% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Duke University Medical Center and Laboratory Corporation of ... formation of a joint venture to commercialize new ... the translation of newly discovered biomarkers into widely ... responses, predict disease progression, and evaluate any number ...
... NASA,s Aqua and Terra satellites fly around the ... land changes. Over the last three days these satellites ... plume from the Eyjafjallajkull volcano in Iceland. Eyjafjallajkull ... spewing ash into the atmosphere. Volcanic eruptions are important ...
... 2010 Scientists from The Scripps Research Institute have provided ... mutations lead to Type 1 diabetes. This new molecular understanding ... other autoimmune diseases. The study was published in an ... on April 19, 2010, and will appear in the ...
Cached Biology News:Duke, LabCorp combine forces to create the Biomarker Factory 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: